Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

54.03

+0.03 (0.06%)

as of Jun 18, 2026, 9:49:29 pm Market Open.

111 watching

TOP PICK

Good yield, but also selling close to its absolute low since 1982. In the meantime everything is happily bubbling along for the company. Excellent upside potential. Partially defensive but also partly aggressive.

PAST TOP PICK

(A Top Pick April 6/10. Up 8.38%.) One of the few drug companies with a good pipeline. A medium size major so has room to grow. Recently got FDA approval for a cancer/melanoma drug. This could be a blockbuster drug.

COMMENT

A good company but prefers Johnson and Johnson (JNJ-N) for the longer term. Pays a good dividend. Strong franchise.

TOP PICK

Likes the US health care pharmaceuticals in general. This one has a nice yield. Selling at a low valuation.

PAST TOP PICK

(A Top Pick Jan 28/10. Up 13.26%.) People don’t like drug companies as many of them have patent cliffs where a lot of their big drugs are coming off patent. This one has a good pipeline of good and promising drugs.

TOP PICK

Good pipeline and a large amount of cash that can be used for acquisitions. Expects they will continue to raise their 4.8% dividend.

TOP PICK

Likes the healthcare area. Cheap compared to the rest of the market. Investors are starting to come into it realizing that negativity towards drug companies had been overdone. Built up a war chest of $3 billion. 5.25% yield.

DON'T BUY

Very cheap on any value metrics but has had a very hard time. Did very well when they had blockbuster drugs but those drugs have come off and it is hard to get them replaced. Prefers Johnson & Johnson (JNJ-N) because it is not a pure pharmaceutical company.

SELL

(Market Call Minute) A drug coming off Patent in 2012 represents 27% of revenues.

TOP PICK

In a trading range of about $22-$28. At $23 or lower it’s a Buy. 5.5% yield. Has a better pipeline of pharmaceutical products than a lot of other competitors. If you got it at these prices and that one up to $25-$26, he would pare it back.

TOP PICK

Likes the pharma space, which has been beaten up badly. What intrigues him is the pill popping baby boomers. Has one of the best profiles on patent expiries. Less than 6% dividend.

DON'T BUY

Not thrilled with the entire pharmaceutical industry.

BUY

(Market Call Minute.) Has a really good dividend yield and have got past their problems of patent expiries and regulatory issues.

HOLD

Pfizer (PFE-N) has a better product pipeline and a higher growth rate. Recently, the stock has been outperforming Pfizer. He thinks they are for sale and is waiting for the right partner to come along. If you own, hold on for the moment.

DON'T BUY

Had many problems in the past with pipeline, patent lawsuits. Now reaching the point where it is a turnaround story. Doesn't see anything happening in the near term that will boost their profitability or the outlook of the company.

Showing 121 to 135 of 191 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Bristol Myers Squibb (BMY)